CELL INTELLIGENCE · 肿瘤细胞治疗研究

丙戊酸钠驱动丙酰化介导的表观遗传重编程以增强间皮素 CAR-T 细胞治疗实体瘤

Sodium valproate drives propionylation-mediated epigenetic reprogramming to enhance mesothelin CAR-T cell therapy in solid tumors.

利用脐血 CD34⁺ HSPC 来源的间皮素特异性 CAR-NKT 细胞靶向三阴性乳腺癌，具有强效抗肿瘤活性

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity.

这些结果支持 Allo15 MCAR-NKT 细胞作为一种下一代、现成的免疫疗法，对 TNBC 具有强大的治疗潜力，特别是在转移、免疫逃逸和治疗耐药的情况下。

嵌合抗原受体 NK 细胞用于乳腺癌免疫治疗

Chimeric antigen receptor NK cells for breast cancer immunotherapy.

分泌 NKG2D-BiTE 的间皮素靶向 CAR-T 细胞对三阴性乳腺癌显示强效疗效

Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer.

质子泵抑制剂减弱酸性微环境以提高 MSLN-CAR-T 细胞对脑转移的治疗效果

Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis.

微环境碱化促进 MSLN-CAR-T 细胞的治疗效果

Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells.

CAR-T 细胞作为不可切除腺癌的辅助治疗

Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma.

经工程改造识别效应沉默型肿瘤抗原靶向人 IgG1 抗体 P329G 突变 Fc 段的 CAR-T 细胞实现实体瘤的模块化靶向

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies

靶向 P329G 的 CAR-T 细胞联合含 P329G Fc 突变的人 IgG1 抗原结合抗体，在不同实体瘤模型中介导了显著的体外和体内效应功能，值得进一步推进该概念的临床转化。

区域间皮素靶向 CAR-T 细胞疗法联合抗 PD-1 药物帕博利珠单抗治疗恶性胸膜疾病患者的 I 期试验

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent

乳腺癌 CAR-T 细胞免疫治疗的知识图谱与研究趋势：一项文献计量学与可视化分析研究

Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.